A comparative study of Botulinum toxin type A versus conventional oral therapy as a second-line treatment of diabetic neuropathy

Table 4 Comparison between the three studied groups according to PSQI

BISP	Duloxetine (n = 10)	Gabapentin (n = 10)	Botox (n = 10)	F	p
PSQI 0
Mean ± SD	17.4 ± 2.2	16.2 ± 2.7	17.3 ± 1.8	0.854	0.437
Median (Min.–Max.)	18 (14–20)	17.5 (12–19)	17.5 (15–20)	0.854	0.437
PSQI 1 week
Mean ± SD	16.7 ± 2.4	15.7 ± 2.6	15.9 ± 2.4	0.464	0.634
Median (Min.–Max.)	17 (14–20)	16.5 (11–19)	16 (12–20)	0.464	0.634
PSQI 4 weeks
Mean ± SD	15 ± 1.6	14.4 ± 3.2	9.9 ± 3.6	9.070^*	0.001^*
Median (Min.–Max.)	14.5 (13–18)	13.5 (9–20)	10 (6–16)	9.070^*	0.001^*
Sig. bet. grps	p₁ = 0.891, p₂ = 0.002^, p₃ = 0.005^
PSQI 12 weeks
Mean ± SD	13.8 ± 2.4	13.3 ± 3	10.9 ± 3.1	2.915	0.071
Median (Min.–Max.)	13 (9–17)	13.5 (9–19)	11 (7–15)	2.915	0.071

SD: standard deviation
F: F for ANOVA test, pairwise comparison bet. Each two groups was done using post hoc test (Tukey)
p: p value for comparing between the three studied groups
p₁: p value for comparing between duloxetine and gabapentin
p₂: p value for comparing between duloxetine and Botox
p₃: p value for comparing between gabapentin and Botox
^*Statistically significant at p ≤ 0.05